key: cord-0987928-tiyuhiyu
authors: Xia, Zilei; Sacco, Michael; Hu, Yanmei; Ma, Chunlong; Meng, Xiangzhi; Zhang, Fushun; Szeto, Tommy; Xiang, Yan; Chen, Yu; Wang, Jun
title: Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir
date: 2021-06-09
journal: ACS Pharmacol Transl Sci
DOI: 10.1021/acsptsci.1c00099
sha: ae4cf6f45ac703f09031bb49c139fa6dd7cd0461
doc_id: 987928
cord_uid: tiyuhiyu

[Image: see text] SARS-CoV-2 main protease (M(pro)) is a cysteine protease that mediates the cleavage of viral polyproteins and is a validated antiviral drug target. M(pro) is highly conserved among all seven human coronaviruses, with certain M(pro) inhibitors having broad-spectrum antiviral activity. In this study, we designed two hybrid inhibitors UAWJ9-36-1 and UAWJ9-36-3 based on the superimposed X-ray crystal structures of SARS-CoV-2 M(pro) with GC-376, telaprevir, and boceprevir. Both UAWJ9-36-1 and UAWJ9-36-3 showed potent binding and enzymatic inhibition against the M(pro)’s from SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-NL63, HCoV-229E, and HCoV-HKU1. Cell-based Flip-GFP M(pro) assay results show that UAWJ9-36-1 and UAWJ9-36-3 inhibited the intracellular protease activity of SARS-CoV-2 M(pro). In addition, UAWJ9-36-1 and UAWJ9-36-3 had potent antiviral activity against SARS-CoV-2, HCoV-OC43, HCoV-NL63, and HCoV-229E, with UAWJ9-36-3 being more potent than GC-376 in inhibiting SARS-CoV-2. Selectivity profiling revealed that UAWJ9-36-1 and UAWJ9-36-3 had an improved selectivity index over that of GC-376 against host cysteine proteases calpain I and cathepsin L, but not cathepsin K. The X-ray crystal structures of SARS-CoV-2 M(pro) with UAWJ9-36-1 and UAWJ9-36-3 were both solved at 1.9 Å, which validated our design hypothesis. Overall, hybrid inhibitors UAWJ9-36-1 and UAWJ9-36-3 are promising candidates to be further developed as broad-spectrum coronavirus antivirals.

S ARS-CoV-2 is the etiological agent of the COVID-19, and it is the third coronavirus that causes significant morbidity and mortality in humans. The other two highly pathogenic coronaviruses are SARS-CoV and MERS-CoV, with mortality rates of 9.7 and 34.3%, 1 respectively. In addition, four common human coronaviruses including HCoV-OC43, HCoV-229E, HCoV-NL63, and HCoV-HKU1 also circulate among humans and cause common colds. SARS-CoV-2 is a single-stranded, positive-sense RNA virus that shares ∼80% sequence identity with SARS-CoV. Although the previous SARS and MERS outbreaks failed to fuel the development of coronavirus antivirals, the current COVID-19 pandemic is a reminder that broad-spectrum antivirals are needed to combat not only existing coronaviruses but also future emerging coronaviruses. In line with this, the viral polymerase and proteases are prominent targets for the development of broad-spectrum anticoronavirus drugs. 2 The viral polymerase inhibitor remdesivir was the first drug that received FDA approval for the treatment of COVID-19 infection, although the results from several clinical trials were not consistent. 3−5 In addition, another viral polymerase inhibitor molnupiravir is currently being studied in a clinical trial. 6, 7 Molnupiravir was originally developed as an oral influenza drug. 8 SARS-CoV-2 encodes two viral proteases, the main protease (M pro ) and the papain-like protease (PL pro ), both of which are validated antiviral drug targets. 9,10 M pro and PL pro are cysteine proteases that cleave the viral polyproteins during viral replication. PL pro plays additional roles in antagonizing the host innate immune response through its deubiquitinating and deISG15ylating (interferon-induced gene 15) activities. 11−13 The active site residues of M pro across different coronaviruses are relatively conserved, and certain M pro inhibitors have shown broad-spectrum antiviral activity. Among the M pro inhibitors reported to date, the most advanced ones are GC-376, 9, 10, 14, 15 6j, 16 PF-07304814, 17 MI-09, MI-30, 18 and the deuterated GC-376 (D2-GC-376) 19 ( Figure 1A ). GC-376 showed in vivo antiviral efficacy in treating cats infected with lethal feline infectious peritonitis virus. 14, 15 A recent study found that GC-376 analog 6j protected mice from MERS-CoV infection. 16 The same group also reported that a deuterated analog of GC-376 (D2-GC-376, compound 2 in the original publication) had in vivo antiviral efficacy in a SARS-CoV-2infected mouse model. 19 PF-07304814 is an α-hydroxyl ketone prodrug that was originally being developed by Pfizer as an antiviral drug for SARS-CoV. 17 It has favorable pharmacokinetic properties and in vivo antiviral efficacy in the SARS-CoVinfected mouse model. PF-07304814 is currently in a phase I clinical trial for COVID-19. 17 Two additional GC-376 analogs, MI-09 and MI-30, were recently reported to protect mice from lethal SARS-CoV-2 infection. 18 These promising results highlight the translational potential of M pro inhibitors as potent SARS-CoV-2 antivirals and validate M pro as an antiviral drug target for coronaviruses.

Our previous high-throughput screening identified GC-376 and boceprevir as SARS-CoV-2 M pro inhibitors with IC 50 values of 0.03 and 4.13 μM, respectively. 9 Telaprevir was less active and inhibited 31% of the M pro enzymatic activity at 20 μM. We subsequently solved the X-ray crystal structure of SARS-CoV-2 M pro with GC-376 and other hits including calpain inhibitors II and XII. 9 , 10 Our results have been independently validated by others at about the same time. Fu et al. reported that GC-376 and boceprevir inhibited SARS-CoV-2 M pro with IC 50 values of 0.15 and 8.0 μM, respectively, 20 and solved the X-ray crystal structure of SARS-CoV-2 M pro with boceprevir. Vuong et al. showed that GC-376 and its active drug GC-373 inhibited SARS-CoV-2 M pro with IC 50 values of 0.40 and 0.19 μM, respectively. 21 Although we reported telaprevir was a weak inhibitor of SARS-CoV-2 M pro (IC 50 > 20 μM), Kneller et al. showed that telaprevir inhibited SARS-CoV-2 M pro with an IC 50 of 18 μM and solved the X-ray crystal structure of SARS-CoV-2 M pro with telaprevir. 22 On the basis of the available X-ray cocrystal structures, we aim to further improve the enzymatic inhibition and cellular antiviral activity of SARS-CoV-2 M pro inhibitors by ACS Pharmacology & Translational Science pubs.acs.org/ptsci Article structure-based drug design. Specifically, the design was guided by overlaying different M pro inhibitors at the active site, and hybrid inhibitors were designed to integrate optimal substitutions at each binding pocket. UAWJ9-36-1 was designed as a hybrid of GC-376 and telaprevir, and UAWJ9-36-3 was designed as a hybrid of GC-376 and boceprevir ( Figure 1B) . Although UAWJ9-36-1 and UAWJ9-36-3 had enzymatic inhibition similar to that of GC-376 in the FRET assay, UAWJ9-36-3 had more potent enzymatic inhibition than GC-376 in the cell-based Flip-GFP M pro assay. The cellular antiviral activity with infectious SARS-CoV-2 further confirmed the superior potency of UAWJ9-36-3 compared to those of UAWJ9-36-1 and GC-376. Hybrid inhibitors UAWJ9-36-1 and UAWJ9-36-3 also inhibited the M pro from other known human coronaviruses including SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-NL63, and HCoV-229E in the FRET-based enzymatic assay, and the binding was confirmed in the thermal shift binding assay. UAWJ9-36-1 and UAWJ9-36-3 also had potent antiviral activity against HCoV-OC43, HCoV-NL63, and HCoV-229E. Selectivity profiling revealed that UAWJ9-36-1 and UAWJ9-36-3 had improved selectivity compared to that of GC-376 against host cysteine proteases calpain I and cathepsin L. We solved the X-ray crystal structures of SARS-CoV-2 M pro with UAWJ9-36-1 and UAWJ9-36-3, which validated our design hypothesis. Overall, designed hybrid inhibitors UAWJ9-36-1 and UAWJ9-36-3 are promising drug candidates for further development as broadspectrum coronavirus antivirals.

Rational Design of SARS-CoV-2 M pro Inhibitors. The superimposed cocrystal structures of GC-376 with telaprevir showed that the pyrrolidone from GC-376 and the norvaline from telaprevir fit in the S1 pocket (Figure 2A−C) . Consistent with its substrate preference for glutamine at the P1 position, pyrrolidone is a preferred substitution where it forms two or three hydrogen bonds with the H163, E166, and F140 in the S1 pocket, while norvaline from telaprevir does not form any specific interaction. The leucine from GC-376 and the cyclopentylproline from telaprevir fit in the S2 hydrophobic pocket (Figure 2A−C) . Since cyclopentylproline forms more hydrophobic interactions than leucine in the S2 pocket, we hypothesize that it might be a preferred substitution at the P2 position. The tert-leucine substitution at the P3 position of telaprevir was solvent-exposed. Because previous structure− activity relationship studies have shown that P3 substitution does not contribute significantly to the enzymatic inhibition, 10 we decided to omit the P3 substitution. The carboxybenzyl (Cbz) group from GC-376 and the cyclohexane from telaprevir fit in the S4 pocket, and both are engaged in hydrophobic interactions. On the basis of the overlaying structures, we designed hybrid inhibitor UAWJ9-36-1, which integrates the favorable substitutions pyrrolidone at the P1, cyclopentylproline at P2, and benzyl at P4 position ( Figure 2D ). Using a similar strategy, UAWJ9-36-3 was designed as a hybrid of GC-376 and boceprevir, which contains dimethylcyclopropylproline at the P2 position (Figure 2A ,E−G).

Synthesis of Hybrid Inhibitors UAWJ9-63-1 and UAWJ9-63-3. The synthesis of UAWJ9-63-1 and UAWJ9-63-3 started with commercially available amino esters 1 and 4 ( Figure 3 ). Protecting the amine with the Cbz and subsequent hydrolysis of the ester gave carboxylic acid intermediates 2 and 5. Subsequent coupling with pyrrolidone intermediate 3, followed by reduction and oxidation, gave final products UAWJ9-36-1 and UAWJ9-36-3. It is noted that the first step Cbz protection of (1S,3aR,6aS)-ethyl octahydrocyclopenta[c]pyrrole-1-carboxylate hydrochloride (1) and methyl (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate hydrochloride (4) led to racemization of the α-chiral center, and H NMR showed a diastereomeric ratio (dr) of 1:1 ( Figure S1 ). It is known from the synthesis of boceprevir, MI-09, and MI-30 that the α-chiral centers at compounds 1 and 4 are prone to racemization. 18, 23 The two diastereomers of final products UAWJ9-36-1 and UAWJ9-36-3 eluted as one broad peak in reverse-phase HPLC and could not be separated ( Figure S2 ). As such, UAWJ9-36-1 and UAWJ9-36-3 were tested in the enzymatic assay and antiviral assay as a diastereomeric mixture (1:1).

Enzymatic Inhibition of UAWJ9-36-1 and UAWJ9-36-3 against the M pro 's from Seven Human Coronaviruses. The enzymatic inhibition activities of UAWJ9-36-1 and UAWJ9-36-3 against the M pro 's from all seven human assay found that UAWJ9-36-1 and UAWJ9-36-3 are potent inhibitors of the M pro 's from all seven human coronaviruses. Cellular Protease Inhibitory Activity of UAWJ9-36-1 and UAWJ9-36-3 in the Flip-GFP M pro Assay. Although the FRET-based enzymatic assay is commonly used as a primary assay for the testing of SARS-CoV-2 M pro inhibitors, the in vitro results from this assay might not have a direct correlation with cellular activity due to issues with drug efflux, cytotoxicity, membrane permeability, metabolism, off-target binding, and so on. 24−26 As such, we developed the Flip-GFP assay to quantify the cellular protease inhibitory activity of UAWJ9-36-1 and UAWJ9-36-3 against SARS-CoV-2 M pro ( Figure 6 ). In the Flip-GFP assay, 293T cells were transfected with two plasmids, one expressing the SARS-CoV-2 M pro and another expressing the Flip-GFP reporter construct with the M pro cleavage site (Flip-GFP M pro ) ( Figure 6A ,B). 27, 28 Specifically, the Flip-GFP M pro reporter construct expresses two GFP fragments, the β10−11 fragment and the β1−9 template. The β10−11 fragment contains an M pro cleavage sequence (AVLQ↓SGFR). Upon cleavage by M pro , the β11 strand will be able to assemble with the β1−9 template together with the β10 strand, leading to the restoration of green fluorescence signal ( Figure 6A ). The Flip-GFP M pro plasmid also expresses the mCherry red fluorescence protein, which serves as an internal control to normalize the protein expression level ( Figure 6B ). As shown in Figure 6C , strong green fluorescence signals were only observed when there is a match between the protease and its corresponding substrate (second and eighth rows). No or minimal GFP signal was observed when there is a mismatch between the protease and its substrate (third, fourth, and fifth rows), no M pro (sixth row), or the inactive M pro (C145A) (seventh row). GC-376 showed dose-dependent inhibition activity in the Flip-GFP M pro assay with an IC 50 of 4.83 μM ( Figure 6D ,G). UAWJ9-36-1 was less active showing an IC 50 of 11.10 μM ( Figures 6E,6G) , while UAWJ9-36-3 was more potent than GC-376 and had an IC 50 value of 3.40 μM (Figures 6D,G) . Overall, the Flip-GFP M pro assay suggested that the UAWJ9-36-1 and UAWJ9-36-3 might have the cellular antiviral activity with a rank of potency in the order of UAWJ9-36-3 > GC-376 > UAWJ9-36-1.

Broad-Spectrum Antiviral Activity of UAWJ9-36-1 and UAWJ9-36-3 against SARS-CoV-2 and Human Figure 7I ,J). The antiviral activity of these two compounds against HCoV-NL63 was tested in two cell lines, Vero E6 and Huh-7 ( Figure 7K−P) . UAWJ9-36-1 and UAWJ9-36-3 were less potent in the Vero E6 cells than in the Huh-7 cells, which might be due to the drug efflux pump Pglycoprotein (P-gp) expressed on the Vero E6 cells. 32 GC-376 and its analogs were previously shown to be the substrates of P-gp. 17, 24, 33 To test this hypothesis, we repeated the antiviral assay in the presence of P-gp inhibitor CP-100356. It was found that the antiviral activity of UAWJ9-36-1 and UAWJ9-36-3 against HCoV-NL63 in Vero E6 cells increased in the presence of CP-100356 ( Figure 7O−P) . Selectivity of UAWJ9-36-1 and UAWJ9-36-3 against human cysteine and serine proteases. Previous studies showed that GC-376 and its analogs also inhibit cathepsin L in addition to the SARS-CoV-2 M pro . 24, 33 In addition, all three 

pubs.acs.org/ptsci Article compounds GC-376, UAWJ9-36-1, and UAWJ9-36-3, contain aldehyde as a reactive warhead; therefore, there might be a potential concern with the off-target effect in inhibiting host cysteine proteases. To test this hypothesis, we profiled the selectivity of these two hybrid compounds against host cysteine proteases calpain I, cathepsin K, cathepsin L, and caspase-3, as well as the serine protease trypsin (Figure 8 ) Table S1 ), revealing a binding pose that is consistent with our projections (Figure 2 ). In the P1 position, we found the pyrroldinone ring interacts with the S1 pocket, forming Hbonds with E166, H163, and the main chain of F140. The cyclopentylproline and dimethylcyclopropylproline moieties of UAWJ9-36-1 and UAWJ9-36-3 occupy the hydrophobic S2 sites almost identically to their telaprevir and boceprevir analogues ( Figure 9E,F) . Interestingly, the Cbz group adopts two different poses in UAWJ9-36-1 and UAWJ9-36-3. In UAWJ9-36-1, the Cbz group adheres to the substrate groove, covering the amide-binding segment of the S3 and S4 sites ( Figure 9B ). In UAWJ9-36-3, the Cbz flips up toward the weakly defined S3 site ( Figure 9C ). The variable binding conformation of the Cbz group has been observed in multiple structures of GC-376 and GC-376 analogues. 10 It is not entirely clear what determines this pose, but given the nonspecific nature of the interactions at the S3 and S4 subsites, it is possible these populations exists in dynamic equilibrium, with individual poses promoted by the crystallization condition and nearby residues. Two different constructs of M pro from our previous studies were used: the native M pro for UAWJ9-36-1 and HM-M pro (with two extra residues in the N-terminus) for UAWJ9-36-3. As the Nterminus of one protomer is in close proximity to the active site of the other protomer in the M pro dimer, this resulted in differences in the conformation of E166 that interacts with the pyrroldinone ring of the inhibitor, which may in turn influence the conformation of the Cbz ring in a specific crystal structure. However, based on previous M pro complex structures, both conformations of the Cbz may be relevant to the activity of the inhibitor, due to the flexible nature and the favorable protein interactions of both conformations.

In parallel to our study, two compounds, MI-09 and MI-30 (Figure 1) , with a similar design were reported to have both in vitro and in vivo antiviral activity against SARS-CoV-2 infection. 18 The results from the hybrid molecules designed in this study UAWJ9-36-1 and UAWJ9-36-3 provided additional evidence to support the translational potential of this series of compounds. Highlights from this study include the following: (1) We solved the X-ray crystal structure of SARS-CoV-2 M pro in complex with both cyclopentylprolinecontaing UAWJ9-36-1 and dimethylcyclopropylproline-containing UAWJ9-36-3, while the previous study only solved the X-ray crystal structure of the cyclopentylproline-containing analog MI-23. 18 Since UAWJ9-36-3 demonstrated more potent antiviral activity than UAWJ9-36-1, the cocrystal structure with UAWJ9-36-3 is valuable in guiding the design of next generation of SARS-CoV-2 M pro inhibitors. (2) We showed that the cell-based Flip-GFP M pro assay is a viable assay that can be used to predict the cellular antiviral activity of M pro inhibitors in a biosafety level 2 (BSL-2) facility. (3) UAWJ9-36-1 and UAWJ9-36-3 demonstrated broad-spectrum antiviral activity against not only SARS-CoV-2 but also common human coronaviruses HCoV-OC43, HCoV-NL63, and HCoV-229E. In addition, both UAWJ9-36-1 and UAWJ9-36-3 also had potent enzymatic inhibition against SARS-CoV and MERS-CoV M pro 's, suggesting they might have antiviral activity against these two viruses. (4) Compared to GC-376 analogs reported to date, 10, 16, 18, 35, 36 UWAJ9-36-3 has superior cellular antiviral activity. (5) We profiled the selectivity of UAWJ9-36-1 and UAWJ9-36-3 against host cysteine proteases and showed that both compounds had a selectivity index improved over that of GC-376 against host proteases calpain I and cathepsin L, but not cathepsin K. Although GC-376 analogs such as MI-09, MI-23, 18 and D2-GC-376 19 were reported to have in vivo antiviral efficacy in a SARS-CoV-2 infection mouse model, their target selectivity and potential cytotoxicity have not been systematically studied, and their long-term side effects are unknown. As all these compounds contain an aldehyde as the reactive warhead, more attention should be given to profiling the selectivity against host cysteine proteases. Only one FDA-approved drug voxelotor contains an aldehyde, and many aldehyde-containing drug candidates were dropped out of clinical trials due to off-target effects. 37 In summary, results from the hybrid inhibitors designed in this study, UAWJ9-36-1 and UAWJ9-36-3, coupled with the in vivo antiviral efficacy from analogs MI-09 and MI-30 reported recently, 18 demonstrated that this series of compounds have great potential to be further developed as broad-spectrum coronavirus antivirals with an improved selectivity index.

Materials and Methods. Chemistry. Chemicals were ordered from commercial sources and were used without further purification. Synthesis procedures for reactions described in Figure 3 are shown below. All final compounds were purified by flash column chromatography. 1 H and 13 C NMR spectra were recorded on a Bruker-400 spectrometer. Chemical shifts are reported in parts per million (ppm) referenced with respect to residual solvent CDCl 3 (7.26 ppm) and internal standard tetramethylsilane (TMS, 0.00 ppm). The following abbreviations were used in reporting spectra: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, doublet of doublets. All reactions were carried out under N 2 atmosphere unless otherwise stated. HPLC-grade solvents were used for all reactions. Flash column chromatography was carried out using silica gel (230−400 mesh, Merck). Lowresolution mass spectra were obtained using an ESI technique on a 3200 Q Trap LC/MS/MS system (Applied Biosystems). The solution of (1S,3aR,6aS)-ethyl octahydrocyclopenta[c]pyrrole-1-carboxylate hydrochloride (1) (5 mmol) and NaHCO 3 (12 mmol) in THF/H 2 O (30 mL, THF/H 2 O = 2:1) was cooled with an ice bath and CbzCl (6 mmol) was added. The reaction was stirred until TLC shows complete consumption of the starting material. The mixture was extracted with CH 2 Cl 2 . The combined organic layer was separated, dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The crude product was used for the next step directly. NMRs showed a diastereomer (dr) mixture was obtained (dr = 1:1). 1 To the solution of the above crude product in THF/H 2 O (30 mL, THF/H 2 O = 2:1) at room temperature was added LiOH (7.5 mmol). The reaction was stirred until TLC shows complete consumption of the starting material. After removing THF, the aqueous layer was washed with hexane/ethyl acetate (hexane/ethyl acetate = 4:1), and the organic layer was discarded. Then, the aqueous layer was adjusted to slightly acidic pH with 1 N HCl and the mixture was extracted with CH 2 Cl 2 /MeOH (CH 2 Cl 2 /MeOH = 15:1). The combined organic layer was separated, dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The obtained acid, 2, was pure enough for later steps.

The solution of acid 2 (1.05 mmol) and amine salt 3 (1 mmol) in DMF was cooled to 0°C with ice batch. DIPEA (4 mmol) was added, followed by HCTU (1.1 mmol). The reaction was warmed to room temperature and stirred overnight. The reaction was added brine and extracted with ethyl acetate. The combined organic layer was successively washed with 1 N HCl, saturated aqueous NaHCO 3 , and brine. Then, the organic layer was dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The crude product was used for the next step directly.

The solution of the above crude product in THF (20 mL) was cooled with an ice bath. LiBH 4 (5 mmol) was added, followed by ethanol (5 mL). The reaction was warmed to room temperature and stirred overnight. After removing THF, the residue was dissolved in water and the pH was adjusted with 1 N HCl to be slightly acidic. The mixture was extracted with CH 2 Cl 2 /MeOH (CH 2 Cl 2 /MeOH = 15:1). The combined organic layer was separated, dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The crude product was used for the next step directly.

The solution of the above crude product in CH 2 Cl 2 (20 mL) was cooled to 0°C with an ice bath. NaHCO 3 (1.5 mmol) was added, followed by Dess-Martin Periodinane (DMP) (1.5 mmol). The reaction was warmed to room temperature and stirred until TLC shows complete consumption of the starting material. The reaction was quenched with saturated aqueous Na 2 S 2 O 3 , followed by saturated aqueous NaHCO 3. The mixture was extracted with CH 2 Cl 2 /MeOH (CH 2 Cl 2 /MeOH = 15:1). The combined organic layer was separated, dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography (CH 2 Cl 2 to CH 2 Cl 2 /MeOH = 15:1) to afford the target product UAWJ9-36-1. 44 (m, 1H) . 13 Compound 5. The title compound was synthesized using the same procedure described above. The installation of Cbz also afforded a dr mixture (dr = 1:1). 1 Cell Lines and Viruses. Human rhabdomyosarcoma (RD, ATCC CCL-136), Vero C1008 (ATCC CRL-1586), Huh-7 (University of Pittsburgh), and HEK293T expressing ACE2 (293T-ACE2, BEI Resources, NR-52511) cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM). Human fibroblast Cell Line, MRC-5 (ATCC CCL-171) was maintained in Eagle's minimum essential medium (EMEM, ATCC 30−2003) . Both media were supplemented with 10% fetal bovine serum (FBS) and 1% penicillin−streptomycin antibiotics. Cells were kept at cell culture incubator (humidified, 5% CO 2 /95% air, 37°C). The following reagents were obtained through BEI Resources, NIAID, NIH: human coronavirus, OC43, NR-52725; human coronavirus, NL63, Studio 5 Real-Time PCR System as previously described 33 with minor modifications. M pro 's were diluted in a buffer containing 20 mM HEPES, pH 6.5, 120 mM NaCl, 0.4 mM EDTA, 4 mM DTT, and 20% glycerol to a final concentration of 4 μM and incubated with serial concentrations of compounds (0.06−200 μM) at 30°C for 1 h. DMSO was included as a reference. SYPRO orange (1×, Thermal Fisher, catalog no.: S6650) was added, and the fluorescence signal was recorded under a temperature gradient ranging from 20 to 95°C (incremental step of 0.05°C s −1 ). The melting temperature (T m ) was calculated as the mid log of the transition phase from the native to the denatured protein using a Boltzmann model in Protein Thermal Shift Software v1.3. ΔT m was calculated by subtracting reference melting temperature of proteins in the presence of DMSO from the T m in the presence of compounds.

Enzymatic Assays. To determine the IC 50 values for GC-376, UAWJ9-36-1, and UAWJ9-36-3, 100 nM SARS-CoV-2, MERS-CoV, SARS-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, or HCoV-HKU1M pro was incubated with serial concentrations of the compounds at 30°C for 30 min in the reaction buffer containing 20 mM HEPES, pH 6.5, 120 mM NaCl, 0.4 mM EDTA, 4 mM DTT, and 20% glycerol. The proteolytic reactions were initiated by adding 10 μM of substrate peptide and recorded in Cytation 5 imaging reader (Thermo Fisher Scientific) with filters for excitation at 360/40 nm and emission at 460/40 nm for 1 h. The initial velocity of the proteolytic reaction was calculated by linear regression for the first 15 min of the kinetic progress curves. IC 50 curve fittings were carried out using log(concentration of compounds) versus the initial velocity with variable slopes in Prism 8.

Kinetic studies of the proteolytic reaction progress curves with GC-376, UAWJ9-36-1, and UAWJ9-36-3 were carried out as follows: First, 5 nM SARS-CoV-2 M pro , 60 nM MERS-CoV M pro , or 5 nM SARS-CoV M pro was added into 20 μM substrate peptide premixed with serial concentrations of the compounds in 200 μL of reaction buffer at 30°C to initiate the proteolytic reaction. The reaction was monitored for 4 h. The progression curves were fitted as previously described. 33 The first 90 min of the kinetic curves were used in the curve fittings as substrate depletion was observed when proteolytic reactions carried out longer than 90 min.

Trypsin assay reactions were carried out as previously described, 34 with minor modifications; 100 μL of reaction solution containing 100 nM Trypsin (Millipore sigma, catalog no.: T6763), 50 mM HEPES (pH7.6), and serial concentrations of GC-376, UAWJ9-36-1, and UAWJ9-36-3 (0, 0.02, 0.06, 0.2, 0.6, 2, 6, and 20 μM) or Camostat (0, 0.002, 0.006, 0.02, 0.06, 0.2, 0.6, and 2 μM) were incubated at 30°C for 30 min. The reactions were initiated by adding 100 μM Bz-Arg-AMC·HCl (BACHEM, Product No.: 4002540.0050). Fluorescence signal intensities were recorded for 20 min using a Biotek Cytation 3 plate reader (Thermo Fisher Scientific) with filters for excitation at 360/40 nm and emission at 460/40 nm, and the initial velocity was calculated for the first 10 min by linear regression. The IC 50 values were determined by curve fittings using log(concentration of compounds) versus the initial velocity with variable slopes in Prism 8.

Calpain I, cathepsin L, and cathepsin K enzymatic assays were carried as previously described. 34 The caspase-3 enzymatic assay was carried out as follows: 1 unit of caspase-3 protein was diluted into 1600 μL of reaction buffer (20 mM HEPES pH7.4, 2 mM EDTA, 0.1% CHAPS, and 5 mM DTT); 100 μL diluted protein was incubated with 1 μL various concentration of testing compounds for 30 min at 30°C; the enzymatic reaction was initiated by adding 1 μL of 2 mM Ac-DEVD-AFC (Medchemexpress, catalog no. HY-P1005). The reaction was monitored a Molecular Devices SpectraMax iD3 plate reader with excitation at 400 nm and emission at 505 nm at 30°C for 1 h. The IC 50 values were calculated as described in the previous section.

Cellular-Based FlipGFP M pro Assay. Plasmid pcDNA3-TEV-flipGFP-T2A-mCherry was purchased from Addgene (catalog no. 124429). SARS-CoV-2 M pro cleavage site (AVLQSGFR) and SARS-CoV-2 PL pro cleavage site (LRGGAPTK) were introduced into pcDNA3-flipGFP-T2A-mCherry via overlapping PCRs to generate a fragment with SacI and HindIII sites at the ends. SARS-CoV-2 M pro and PL Pro expression plasmids pcDNA3.1 SARS-CoV-2 M pro and pcDNA3.1 SARS-CoV-2 PL Pro were ordered from Genscript (Piscataway NJ) with codon optimization. pcDNA3.1 SARS-CoV-2 M pro -C145A was generated by site-directed Quikchange mutagenesis.

First, 293T cells were seeded in 96-well black, clearbottomed Greiner plate (catalog no. 655090) and reached 70− 90% confluency overnight. Next, 50 ng of pcDNA3-flipGFP-T2A-mCherry plasmid with TEV, PL pro , or M pro cleavage site and 50 ng of protease expression plasmid pcDNA3.1 SARS-CoV-2 M pro or SARS-CoV-2 PL pro were transfected into 293T cells with transfection reagent TransIT-293 (Mirus catalog no. MIR 2700) according to the manufacturer's protocol. Three hours after transfection, 1 μL of testing compound was added to each well at 100-fold dilution. Two days after transfection, images were taken with Cytation 5 imaging reader (Biotek) using GFP and mCherry channels via 10× objective lens and were analyzed with Gen5 3.10 software (Biotek). SARS-CoV-2 M pro protease activity was calculated as the ratio of GFP signal ACS Pharmacology & Translational Science pubs.acs.org/ptsci Article sum intensity over mCherry signal sum intensity. Testing compounds efficacy (IC 50 ) in cells was calculated by plotting GFP/mCherry signal over the applied compound concentration with a 4-parameter dose−response function in prism 8. The mCherry signal alone in the presence of testing compounds was utilized to evaluate the compound cytotoxicity. Antiviral Assays. The antiviral activities of GC-376, UAWJ9-36-1, and UAWJ9-36-3 against HCoV-229E and HCoV-NL63 were detected via the CPE assay as previously described. 33, 38 Briefly, near-confluent MRC-5 cells and Vero C1008 cells in 96-well plates were infected with 100 μL of HCoV-229E and HCoV-NL63 at desired dilutions and incubated at 33 or 37°C for 1 h. Different concentrations of testing compounds (0, 0.015, 0.05, 0.15, 0.5, 1.5, 3, 5, and 15 μM) were added, and the infected cells were incubated for another 3−5 days until significant cytopathic effect was observed in the wells without compound (virus only). The growth medium was removed, and cells were stained with 0.1 mg/mL neutral red for 2 h. Excess dye was rinsed from the cells with PBS. The neutral red dye which was taken up was extracted from the cells with a buffer containing 50% ethanol and 1% glacial acetic acid. The absorbance of neutral red dye at 540 nm was measured on a spectrometer. The antiviral activity of GC-376, UAWJ9-36-1, and UAWJ9-36-3 was tested against HCoV-OC43 in plaque assay. RD cells were infected with HCoV-OC43 and incubated at 33°C for 1 h to allow virus adsorption. The viral inoculum was removed, and an overlay containing 0.2% Avicel supplemented with 2% FBS in DMEM containing serial concentrations of testing compounds (0, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1 μM) was added and incubated in the 33°C incubator for 4−5 days. The plaque formation was detected by staining the cell monolayer with crystal violet, and the plaque areas were quantified using ImageJ. EC 50 values were determined by plotting the percent CPE versus log 10 compound concentrations from best-fit dose response curves with variable slope in Prism 8.

SARS-CoV-2 M pro Crystallization and Structure Determination. SARS-CoV-2 M pro and HM-M pro protein was purified, and crystals were grown as previously described. 9 ,10 X-ray diffraction data was collected on the Structural Biology Center 19-ID beamline at the Advanced Photon Source in Argonne, IL, and processed with the iMosflm. The CCP4 version of MOLREP was used to solve the structures of UAWJ9-36-1 + SARS-CoV-2 M pro using 7KX5 as a reference model and UAWJ9-36-3 + SARS-CoV-2 HM-M pro with 6XBI as a reference model. Structures were then refined with REFMAC5 and built with COOT. 39, 40 All protein structure figures were generated with PyMOL (Schrodinger, LLC).

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsptsci.1c00099. Crystallization statistics; H and C NMR; HPLC traces; HRMS (PDF)

Utah State University) and amplified in Huh-7 or MRC-5 cells. Protein Expression and Purification. The genes encoding SARS-CoV-2 main protease (accession no.: 7BUY_A), SARS-CoV main protease (accession no.: 6W79_A), MERS-CoV main protease (accession no.: 5C3N_B), HCoV-229E main protease (accession no.: P0C6X1), HCoV-OC43 main protease (accession no.: QDH43723), HCoV-NL63 main protease (accession no.: 5GWY_A), HCoV-HKU1 main protease (accession no.: 3D23_D) were purchased from GenScript (Piscataway, NJ) with Escherichia coli codon optimization and inserted into pET29a(+) plasmid. The M pro genes were then subcloned into the pE-SUMO plasmid as previously described

219461) and cathepsin L (catalog no. 219402) were purchased from EMD Millipore. Calpain I (catalog no. C6108) and trypsin (catalog no. T6763) were purchased from Sigma-Aldrich

M pro 's was detected by differential scanning fluorimetry (DSF) using a Thermal Fisher Quant-(ADHS18-198859) to J.W. We thank Michael Kemp for assistance with crystallization and X-ray diffraction data collection. We also thank the staff members of the Advanced Photon Source of Argonne National Laboratory, particularly those at the Structural Biology Center (SBC), with X-ray diffraction data collection. SBC-CAT is operated by UChicago Argonne, LLC, for the U.S. Department of Energy, Office of Biological and Environmental Research under contract DE-AC02-06CH11357. The SARS-CoV-2 experiments were supported by a COVID-19 pilot grant from UTHSCSA and NIH grant AI151638 to Y.X. SARS-related Coronavirus 2

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics

Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV

Remdesivir for the treatment of Covid-19 -final report

Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial

Repurposed antiviral drugs for Covid-19 -interim WHO solidarity trial results

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Therapeutically administered ribonucleoside analogue MK-4482/ EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L

Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2

Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

broad-spectrum coronavirus protease inhibitor

3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice

Discovery of a novel inhibitor of coronavirus 3CL protease as a clinical candidate for the potential treatment of COVID-19. bioRxiv (Pharmacology and Toxicology)

SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model

) Post-infection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infectio n. bioRxiv (Microbiolo gy

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

Malleability of the SARS-CoV-2 3CL Mpro active-site cavity facilitates binding of clinical antivirals

Synthesis and process optimization of boceprevir: a protease inhibitor drug

Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19

Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors

Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors

Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models. bioRxiv (Pharmacology and Toxicology

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells

2020) Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells

Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis

Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses

Expedited approach towards the rational design of non-covalent SARS-CoV-2 main protease inhibitors

Bepridil is potent against SARS-CoV-2 in vitro

Alpha-ketoamides as broadspectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment

Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors

The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor

REFMAC5 for the refinement of macromolecular crystal structures

Coot: model-building tools for molecular graphics

J.W. conceived and designed the study; Z.X. synthesized and characterized the compounds. M.S. carried out M pro crystallization and structure determination, and analyzed the data with Y.C. Y.H. carried out the enzymatic assay, thermal shift binding assay, and antiviral assay against HCoV-OC43, HCoV-NL63, and HCoV-229E. C.M. expressed the SARS-CoV-2 M pro and PL pro and carried out Flip-GFP assay and the counter-screening against host proteases. T.S. expressed the M pro 's from MERS, NL63, 229E, and HKU1. X.M. and F.Z. carried out the SARS-CoV-2 immunofluorescence assay in Vero E6 and Caco2-ACE2 cells under the guidance of Y.X.; J.W. and Y.C. secured funding and supervised the study. J.W. wrote the manuscript with the input from others.